Short answer
Medpace Holdings Inc (MEDP) filed its Q2 2026 10-Q quarterly report on Jul 23, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $707M (up 17.2% year over year) with net income of $121M.
Q2 2026 key financials · XBRL
- Revenue
- $707M
- +17.2% YoY · +0.1% QoQ
- Net income
- $121M
- +34.5% YoY · −2.0% QoQ
- Operating margin
- 20.8%
- EPS (diluted)
- $4.25
- +36.2% YoY · −0.7% QoQ
Source: XBRL data from the Medpace Holdings Inc (MEDP) Q2 2026 10-Q on SEC EDGAR. USD.
Medpace Holdings Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $707.3M, up 17.2% YoY from $603.3M, driven by Metabolic, Oncology, CNS and AVAI
- Operating margin 20.8% vs 20.9% YoY, net income $121.4M vs $90.3M
- Net new awards $795.7M, up from $620.5M; backlog $3,014.2M, up 4.9% YoY
- Cash $502.7M vs $497.0M at December 31, 2025; six-month operating cash flow $313.8M
- Capital spending 2.17% of revenue, up 78 basis points; liquidity expected sufficient over next 12 months and longer term
Risk Factors
- No significant changes to previously disclosed risk factors in the fiscal 2025 Form 10-K
- Share repurchase activity: $294.7 million returned to shareholders during fiscal 2026 second quarter
- Liquidity allocation: $526,985,940 remained available under the repurchase plan as of May 31, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.